Show simple item record

dc.contributor.authorFrentz, Dinekeen_US
dc.contributor.authorVan de Vijver, David A. M. C.en_US
dc.contributor.authorAbecasis, Ana B.en_US
dc.contributor.authorAlbert, Janen_US
dc.contributor.authorHamouda, Osamahen_US
dc.contributor.authorJørgensen, Louise B.en_US
dc.contributor.authorKücherer, Claudiaen_US
dc.contributor.authorStruck, Danielen_US
dc.contributor.authorSchmit, Jean-Claudeen_US
dc.contributor.authorVercauteren, Jurgenen_US
dc.contributor.authorÅsjø, Birgittaen_US
dc.contributor.authorBalotta, Claudiaen_US
dc.contributor.authorBeshkov, Danailen_US
dc.contributor.authorCamacho, Ricardo J.en_US
dc.contributor.authorClotet, Bonaventuraen_US
dc.contributor.authorCoughlan, Suzieen_US
dc.contributor.authorGriskevicius, Algirdasen_US
dc.contributor.authorGrossman, Zehavaen_US
dc.contributor.authorHorban, Andrzejen_US
dc.contributor.authorKolupajeva, Tatjanaen_US
dc.contributor.authorKorn, Klausen_US
dc.contributor.authorKostrikis, Leondios G.en_US
dc.contributor.authorLiitsola, Kirsien_US
dc.contributor.authorLinka, Mareken_US
dc.contributor.authorNielsen, Clausen_US
dc.contributor.authorOtelea, Danen_US
dc.contributor.authorParaskevis, Dimitriosen_US
dc.contributor.authorParedes, Rogeren_US
dc.contributor.authorPoljak, Marioen_US
dc.contributor.authorPuchhammer-Stöckl, Elisabethen_US
dc.contributor.authorSönnerborg, Andersen_US
dc.contributor.authorStanekova, Danicaen_US
dc.contributor.authorStanojevic, Majaen_US
dc.contributor.authorVan Wijngaerden, Ericen_US
dc.contributor.authorWensing, Annemarie M. J.en_US
dc.contributor.authorBoucher, Charles A. B.en_US
dc.contributor.authoron behalf of the SPREAD Programmeen_US
dc.description.abstractBackground: One out of ten newly diagnosed patients in Europe was infected with a virus carrying a drug resistant mutation. We analysed the patterns over time for transmitted drug resistance mutations (TDRM) using data from the European Spread program. Methods: Clinical, epidemiological and virological data from 4317 patients newly diagnosed with HIV-1 infection between 2002 and 2007 were analysed. Patients were enrolled using a pre-defined sampling strategy. Results: The overall prevalence of TDRM in this period was 8.9% (95% CI: 8.1-9.8). Interestingly, significant changes over time in TDRM caused by the different drug classes were found. Whereas nucleoside resistance mutations remained constant at 5%, a significant decline in protease inhibitors resistance mutations was observed, from 3.9% in 2002 to 1.6% in 2007 (p = 0.001). In contrast, resistance to non-nucleoside reverse transcriptase inhibitors (NNRTIs) doubled from 2.0% in 2002 to 4.1% in 2007 (p = 0.004) with 58% of viral strains carrying a K103N mutation. Phylogenetic analysis showed that these temporal changes could not be explained by large clusters of TDRM. Conclusion: During the years 2002 to 2007 transmitted resistance to NNRTI has doubled to 4% in Europe. The frequent use of NNRTI in first-line regimens and the clinical impact of NNRTI mutations warrants continued monitoring.en_US
dc.publisherBioMed Centraleng
dc.rightsAttribution CC BYeng
dc.titleIncrease in transmitted resistance to non-nucleoside reverse transcriptase inhibitors among newly diagnosed HIV-1 infections in Europeen_US
dc.typePeer reviewed
dc.typeJournal article
dc.rights.holderCopyright 2014 Frentz et al.; licensee BioMed Central Ltd.
dc.rights.holderDineke Frentz et al.; licensee BioMed Central Ltd.
dc.source.journalBMC Infectious Diseases

Files in this item


This item appears in the following Collection(s)

Show simple item record

Attribution CC BY
Except where otherwise noted, this item's license is described as Attribution CC BY